2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A
According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.
You may also be interested in...
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?